Literature DB >> 11286676

Creating therapeutic cancer vaccines: notes from the battlefield.

W W Overwijk, N P Restifo.   

Abstract

With the identification of tumor antigens and a knowledge of how to vaccinate against them, the field of tumor immunology faces new challenges. In this article, the authors argue that successful immunotherapies of the future will activate anti-tumor T cells without inducing their anergy or apoptotic death.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11286676      PMCID： PMC1679661          DOI： 10.1016/s1471-4906(00)01793-2

Source DB:  PubMed          Journal:  Trends Immunol        ISSN： 1471-4906            Impact factor:   16.687


  33 in total

Review 1.  A new era for cancer immunotherapy based on the genes that encode cancer antigens.

Authors:  S A Rosenberg
Journal:  Immunity       Date:  1999-03       Impact factor: 31.745

Review 2.  T cell clonal anergy.

Authors:  R H Schwartz
Journal:  Curr Opin Immunol       Date:  1997-06       Impact factor: 7.486

Review 3.  The new vaccines: building viruses that elicit antitumor immunity.

Authors:  N P Restifo
Journal:  Curr Opin Immunol       Date:  1996-10       Impact factor: 7.486

4.  Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.

Authors:  S A Rosenberg; Y Zhai; J C Yang; D J Schwartzentruber; P Hwu; F M Marincola; S L Topalian; N P Restifo; C A Seipp; J H Einhorn; B Roberts; D E White
Journal:  J Natl Cancer Inst       Date:  1998-12-16       Impact factor: 13.506

5.  Immune surveillance against a solid tumor fails because of immunological ignorance.

Authors:  A F Ochsenbein; P Klenerman; U Karrer; B Ludewig; M Pericin; H Hengartner; R M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

6.  Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100.

Authors:  M C Panelli; J Wunderlich; J Jeffries; E Wang; A Mixon; S A Rosenberg; F M Marincola
Journal:  J Immunother       Date:  2000 Jul-Aug       Impact factor: 4.456

7.  A "stealth effect": adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions.

Authors:  M Giovarelli; P Musiani; G Garotta; R Ebner; E Di Carlo; Y Kim; P Cappello; L Rigamonti; P Bernabei; F Novelli; A Modesti; A Coletti; A K Ferrie; P L Lollini; S Ruben; T Salcedo; G Forni
Journal:  J Immunol       Date:  1999-11-01       Impact factor: 5.422

8.  Contemporary analysis of MHC-related immunodominance hierarchies in the CD8+ T cell response to influenza A viruses.

Authors:  G T Belz; P G Stevenson; P C Doherty
Journal:  J Immunol       Date:  2000-09-01       Impact factor: 5.422

9.  Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.

Authors:  S A Rosenberg; D E White
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1996-01

10.  Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen.

Authors:  M Wang; V Bronte; P W Chen; L Gritz; D Panicali; S A Rosenberg; N P Restifo
Journal:  J Immunol       Date:  1995-05-01       Impact factor: 5.422
View more
  8 in total

1.  Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant.

Authors:  Willem W Overwijk; Karin E de Visser; Felicia H Tirion; Laurina A de Jong; Thijs W H Pols; Yme U van der Velden; Jasper G van den Boorn; Anna M Keller; Wim A Buurman; Marc R Theoret; Bianca Blom; Nicholas P Restifo; Ada M Kruisbeek; Robert A Kastelein; John B A G Haanen
Journal:  J Immunol       Date:  2006-05-01       Impact factor: 5.422

Review 2.  Cancer vaccines: progress reveals new complexities.

Authors:  Zhiya Yu; Nicholas P Restifo
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

3.  Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses.

Authors:  C Siddiq Abdul-Alim; Yongqing Li; Cassian Yee
Journal:  J Immunol       Date:  2010-05-07       Impact factor: 5.422

Review 4.  Immunotherapy for lymphomas.

Authors:  John M Timmerman
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

Review 5.  Adenosine receptors and cancer.

Authors:  P Fishman; S Bar-Yehuda; M Synowitz; J D Powell; K N Klotz; S Gessi; P A Borea
Journal:  Handb Exp Pharmacol       Date:  2009

6.  Potent Antitumor Activity Generated by a Novel Tumor Specific Cytotoxic T Cell.

Authors:  Zheng Wang; Pei Li; Qinhong Xu; Jun Xu; Xuqi Li; Xufeng Zhang; Qingyong Ma; Zheng Wu
Journal:  PLoS One       Date:  2013-06-18       Impact factor: 3.240

7.  Pancreatic carcinoma-specific immunotherapy using novel tumor specific cytotoxic T cells.

Authors:  Jianjun Lei; Zheng Wu; Zhengdong Jiang; Jiahui Li; Liang Zong; Xin Chen; Wanxing Duan; Qinhong Xu; Lun Zhang; Liang Han; Qingyong Ma; Zheng Wang; Dong Zhang
Journal:  Oncotarget       Date:  2016-12-13

Review 8.  Adenosine Targeting as a New Strategy to Decrease Glioblastoma Aggressiveness.

Authors:  Valentina Bova; Alessia Filippone; Giovanna Casili; Marika Lanza; Michela Campolo; Anna Paola Capra; Alberto Repici; Lelio Crupi; Gianmarco Motta; Cristina Colarossi; Giulia Chisari; Salvatore Cuzzocrea; Emanuela Esposito; Irene Paterniti
Journal:  Cancers (Basel)       Date:  2022-08-20       Impact factor: 6.575
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.